Administration Rightly Diagnoses Big Pharma’s Egregious Pricing Practices as
Root Cause of High Drug Prices in America, Can Help Lower Prices by Supporting
Solutions to Boost Competition





 



CSRXP STATEMENT ON PRESIDENT TRUMP’S MOST FAVORED NATION EXECUTIVE ORDER

Administration Rightly Diagnoses Big Pharma’s Egregious Pricing Practices as
Root Cause of High Drug Prices in America, Can Help Lower Prices by Supporting
Solutions to Boost Competition



For Immediate Release

May 13, 2025



Contact: Jon Conradi

[email protected] <mailto:[email protected]>



Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued the
following statement on Tuesday on President Trump's signing of an executive
order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to
American Patients.”



“CSRxP appreciates President Trump’s commitment to lowering prescription drug
prices in America, and for rightly diagnosing the egregious prices set by Big
Pharma as the root cause of the problem,” said CSRxP spokesman Jon Conradi.
“CSRxP looks forward to reviewing the full details of the policy initiatives
outlined by the recent executive order and encourages the Administration to
build on its commitment to lowering drug prices for patients now, by lending
its strong support to bipartisan, bicameral work on Capitol Hill to hold Big
Pharma accountable for egregious abuse of the U.S. patent system that costs
American patients and taxpayers billions of dollars each year.”



A recent national survey
<[link removed]>
of U.S. voters, commissioned by CSRxP and conducted by Trump campaign pollster
Fabrizio Ward, found Americans continue to be very concerned with high drug
prices, hold drug companies responsible for high drug prices and support
market-based solutions to lower prices by holding big drug companies
accountable, including for gaming the U.S. patent system to block competition.

* Nine in ten voters expressed concern about the cost of prescription drugs
in the U.S.


* 62 percent of voters view drug companies as the most responsible for high
drug costs out of eight options.


* 82 percent of voters support patent reforms to prevent drug companies from
abusing the system to prevent cheaper alternatives from entering the market.
“The electorate, including equal numbers of Trump and Harris Voters, holds
intensely unfavorable views of drug companies,” pollsters Tony Fabrizio and Bob
Ward wrote in a memo on their findings. “By wide margins, voters are very
concerned about the cost of Rx drugs, hold drug companies responsible and
clearly identify drug company profits as the driver of high drug costs. Members
of Congress, including Republicans, would ignore this extraordinary voter
sentiment at their peril. In fact, Republicans on the Hill should be looking to
the White House for guidance on this issue as Trump Voters trust the President
over Republicans in Congress by a three-to-one margin to address the issue of
prescription drug prices.”



Learn more on Big Pharma’s patent abuse that blocks competition and keeps drug
prices highHERE
<[link removed]>
.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>